Dr. Lal PathLabs Limited reported strong financial results for Q3 FY25, showcasing double-digit revenue growth and a healthy improvement in profitability. The company’s revenue from operations increased to Rs 597 crore, reflecting an 11% YoY growth from Rs 539 crore in Q3 FY24, and a sequential dip from Rs 660 crore in Q2 FY25 due to seasonal demand variations. Total income stood at Rs 622 crore compared to Rs 557 crore in the same quarter last year.
The company’s expenses for the quarter amounted to Rs 483 crore, up 9% YoY from Rs 441 crore in Q3 FY24, driven primarily by higher material costs and employee benefits expenses. Profit before tax improved to Rs 138 crore, up from Rs 116 crore YoY, while tax expenses stood at Rs 40 crore for the quarter. Net profit surged to Rs 98 crore, marking a 19% YoY increase compared to Rs 82 crore in Q3 FY24. Sequentially, net profit showed a marginal decline from Rs 130 crore in Q2 FY25.
The company’s key expense components included Rs 117 crore for materials consumed and Rs 126 crore for employee benefits. Depreciation expenses were stable at Rs 35 crore. The company attributed its strong YoY growth to an increase in diagnostic services volume and operational efficiency improvements.
Dr. Lal PathLabs continues to focus on network expansion and innovation in diagnostic offerings to maintain its growth trajectory while addressing evolving market demands.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
